for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Assertio Holdings Inc

ASRT.O

Latest Trade

2.14USD

Change

-0.19(-8.15%)

Volume

965,324

Today's Range

2.13

 - 

2.30

52 Week Range

0.85

 - 

5.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.33
Open
2.19
Volume
965,324
3M AVG Volume
30.52
Today's High
2.30
Today's Low
2.13
52 Week High
5.80
52 Week Low
0.85
Shares Out (MIL)
44.63
Market Cap (MIL)
104.00
Forward P/E
-33.29
Dividend (Yield %)
--

Next Event

Assertio Holdings Inc at Sidoti & Company Winter Small Cap Conference (Virtual)

Latest Developments

More

Assertio Holdings Announces Acquisition Of Otrexup

Assertio Holdings QTRLY Loss Per Share $0.32

Assertio Reports First Quarter 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Assertio Holdings Inc

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company's commercial portfolio of branded products focuses on three areas: neurology, hospital, and pain and inflammation. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO (oxycodone HCI, USP) tablets, SPRIX (ketorolac tromethamine) Nasal Spray, and ZIPSOR (diclofenac potassium) Liquid filled capsules. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. CAMBIA (diclofenac potassium) is used for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

Industry

Biotechnology & Drugs

Contact Info

100 S. Saunders Road, Suite 300

LAKE FOREST, IL

60045

United States

+1.224.4197106

https://www.assertiotx.com/

Executive Leadership

Peter D. Staple

Independent Chairman of the Board

Daniel A. Peisert

President, Chief Executive Officer, Director

Paul Schwichtenberg

Chief Financial Officer, Senior Vice President

Ajay Patel

Senior Vice President, Chief Accounting Officer

Heather L. Mason

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.3K

2019

0.2K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

4.880

2019

1.880

2020

-0.080

2021(E)

-0.070
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.96
Price To Book (MRQ)
1.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
81.22
LT Debt To Equity (MRQ)
68.56
Return on Investment (TTM)
-15.11
Return on Equity (TTM)
-9.57

Latest News

Latest News

Plaintiffs' lawyers seek $113 million fee in Glumetza pay-for-delay case

Lawyers for purchasers of the diabetes drug Glumetza have asked a judge to approve a fee award of about $113 million after securing more than $453 million from Bausch Health Companies Inc, Lupin Pharmaceuticals Inc and Assertio Therapeutics Inc to settle claims of anticompetitive...

Bausch, Assertio, Lupin must face antitrust claims over diabetes drug Glumetza

Bausch Health Cos Inc, Assertio Therapeutics Inc and Lupin Pharmaceuticals Inc must face claims by purchasers of Bausch's type 2 diabetes drug Glumetza that they conspired to suppress generic competition through an illegal patent settlement, enabling an 800% price hike in...

BRIEF-Assertio Completes Merger With Zyla Life Sciences

* ASSERTIO COMPLETED MERGER WITH ZYLA LIFE SCIENCES Source text for Eikon: Further company coverage:

BRIEF-Assertio Therapeutics Announces First-Quarter 2020 Results

* ASSERTIO THERAPEUTICS - MERGER WITH ZYLA LIFE SCIENCES ON TRACK, EXPECTED TO CLOSE SHORTLY AFTER CO'S 2020 ANNUAL MEETING

BRIEF-Assertio Therapeutics Agrees To Merge With Zyla Life Sciences

* PRESS RELEASE - ASSERTIO THERAPEUTICS AGREES TO MERGE WITH ZYLA LIFE SCIENCES TO CREATE SYNERGISTIC PORTFOLIO OF NEUROLOGY AND NON-OPIOID PAIN PRODUCTS

IN BRIEF: Assertio Therapeutics defeats investors' opioid marketing case

A federal judge on Wednesday dismissed a shareholder lawsuit alleging Assertio Therapeutics Inc misled investors about the extent to which its growth was fueled by marketing its Nucynta opioid painkillers for off-label purposes.

BRIEF-Assertio Therapeutics Posts Fourth-Quarter Loss Per Share Of $2.65

* ASSERTIO THERAPEUTICS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

BRIEF-Assertio Therapeutics Announces Repurchase Of About $188 Mln Of Its Outstanding Convertible Debt

* ASSERTIO THERAPEUTICS ANNOUNCES REPURCHASE OF APPROXIMATELY $188.0 MILLION OF ITS OUTSTANDING CONVERTIBLE DEBT

BRIEF-Assertio Therapeutics Announces Sale Of Nucynta Franchise To Collegium Pharmaceutical For $375.0 Million

* ASSERTIO THERAPEUTICS ANNOUNCES SALE OF NUCYNTA® FRANCHISE TO COLLEGIUM PHARMACEUTICAL FOR $375.0 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up